Gilead Sciences agreed to acquire Arcellx in a $7.8 billion transaction that brings the BCMA‑directed CAR‑T therapy anito‑cel fully under Gilead’s control. The deal consolidates development and commercial rights as anito‑cel’s Biologics License Application remains under FDA review with a PDUFA target date later this year. The acquisition fast‑tracks Gilead’s push into autologous cell therapy and aims to position anito‑cel against established BCMA competitors in multiple myeloma. Arcellx will be folded into Gilead’s cell‑therapy operations, eliminating prior co‑development terms and simplifying commercialization planning. The buyout follows positive pivotal data cited by both companies and reflects pharma consolidation dynamics where large incumbents absorb clinical‑stage cell therapy platforms to secure differentiated products and worldwide rights.